Humabiologics, Inc., a leading biotechnology company specializing in human-derived biomaterials for regenerative medicine, announced that it has been awarded two new patents by the United States Patent and Trademark Office (USPTO). These patents recognize the company’s innovative processes for producing high-quality collagen and gelatin products from human sources, paving the way for advancements in wound healing, tissue regeneration, and 3D bioprinting. These materials offer superior biocompatibility and clinical relevance compared to traditional animal-derived, recombinant, or synthetic alternatives.

The first patent, “Process for production of a soluble and insoluble collagen product from mammalian dermis tissue”, protects Humabiologics’ unique method for producing both soluble and insoluble collagen. This process yields intact native collagen with superior strength and stability, ideal for creating scaffolds for tissue regeneration and developing bioinks for 3D-bioprinted organs, organoids, tissue models, and several tissue engineering and regenerative medicine applications. The patent also provides a method to create the market’s first human collagen-based medical devices for soft tissue repairs, wound healing, and other clinical applications.

The second patent, “Bone gelatin process”, covers Humabiologics’ innovative process for producing bone gelatin. This method results in a highly biocompatible material that has shown promise in promoting cell growth and differentiation, crucial for applications like wound healing and bone regeneration. The bone gelatin can be further processed, for example, through methacrylation to provide a bone gelatin with unique properties that meets the requirements of the growing 3D bioprinting industry.

“These patents are a significant milestone for Humabiologics and the field of regenerative medicine,” said Dr. Mohammad Albanna, CEO and founder of Humabiologics. “Our innovative processes allow us to produce human-derived collagen and gelatin with exceptional quality and versatility, empowering researchers to develop the next generation of regenerative therapies.”

These patents solidify Humabiologics’ position as a leader in the development of human-derived biomaterials for regenerative medicine. The company’s commitment to innovation and quality is driving the development of more effective and clinically relevant therapies worldwide.

About Humabiologics, Inc.
Humabiologics is a pioneering biotechnology company focused on the development and production of native human-derived biomaterials for regenerative therapies and tissue engineering applications. Committed to advancing the field of regenerative medicine, Humabiologics provides high-quality, affordable biomaterials that meet the highest ethical and regulatory standards. The company’s innovative products are used by researchers worldwide to drive advancements in tissue engineering, wound healing, and drug discovery. Humabiologics is headquartered in Phoenix, Arizona.

Media Contact
Jacob Ruelas
602-786-6289
info@humabiologics.com